Allison Luo
Directeur Technique/Scientifique/R&D chez PROMETHEUS BIOSCIENCES, INC.
Profil
Allison Luo is currently working as Senior VP-Gastroenterology at Biora Therapeutics, Inc. and as Chief Medical Officer at Prometheus Biosciences, Inc. She previously worked as Medical Director at Abbott Laboratories, Executive Director at Bristol Myers Squibb Co., and Vice President-Clinical Development at IVERIC bio, Inc. Dr. Luo completed her undergraduate and doctorate degrees from Northwestern University.
Postes actifs de Allison Luo
| Sociétés | Poste | Début |
|---|---|---|
| PROMETHEUS BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 01/08/2018 |
Anciens postes connus de Allison Luo
| Sociétés | Poste | Fin |
|---|---|---|
| BIORA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/08/2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Directeur/Membre du Conseil | 01/10/2014 |
| IVERIC BIO, INC. | Corporate Officer/Principal | - |
| ABBOTT LABORATORIES | Directeur Technique/Scientifique/R&D | - |
Formation de Allison Luo
| Northwestern University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| BIORA THERAPEUTICS, INC. | Health Services |
| Entreprise privées | 2 |
|---|---|
Prometheus Biosciences, Inc.
 Prometheus Biosciences, Inc. BiotechnologyHealth Technology Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA . | Health Technology |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
